Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb study of LIB-01 for the treatment of erectile dysfunction

Next Previous
Trial Profile

A phase IIb study of LIB-01 for the treatment of erectile dysfunction

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LIB 01 (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors Dicot

Most Recent Events

  • 30 Apr 2026 According to Dicot Pharma media release, on April 28, it was announced that the Board of Directors of Dicot Pharma intends to resolve on a rights issue of units totaling approximately SEK 210 million before transaction costs to finance the planned phase 2b study with LIB-01.
  • 12 Mar 2026 According to Dicot Pharma media release, company announced that a tablet formulation with good properties and good stability for use in clinical studies has been successfully developed based on previous oral formulations. This week, the manufacture of tablets with active substance and placebo to be used in the phase 2b study began.
  • 12 Mar 2026 According to Dicot Pharma media release, the company has successfully completed the development of LIB-01 as a tablet and initiated manufacturing of tablets ahead of the upcoming phase 2b clinical study. The plan is to initiate the clinical study in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top